Startup gobbles up $60M from high-profile investors to target food allergies

A narrow band of proteins that run through dozens of food allergies helped a California startup swallow $60 million from a syndicate of investors — including high-powered families — to develop a broad food allergy treatment. Alladapt Immunotherapeutics Inc. — a Menlo Park, Calif., company launched in 2018 by early 23andMe Inc. executive Ashley Dombkowski — expects to use the Series C funding to take its lead drug into a clinical tria l later this year. The oral drug is designed to provoke…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news